Kymera Therapeutics announces presentations on KT-621, a first-in-class, oral Stat6 degrader, at the Society for Investigative Dermatology and American Thoracic Society congresses

Published: 2026-05-15 07:14:24 ET KYMR

Published on 05/15/2026 at 07:14 am EDT